programas cribado cancer

Nota bibliográfica cribado c mama 2012-06

Allan H. Benefits and harms of mammography screening editorial. BMJ 2012 Jan 6;344.  DOI: 10.1136/bmj.d8279
Ascunce N, Delfrade J, Salas D, Zubizarreta R, Ederra M, en nombre de Red de Program. Programas de detección precoz de cáncer de mama en España: características y principales resultados. Med Clin (Barc ) 2012 Jun 13.  DOI: S0025-7753(12)00414-9 [pii];10.1016/j.medcli.2012.03.030 [doi]
CONCLUSIONS: Despite the variability evident in the data provided by the different autonomous communities and the need to improve the homogeneity of information systems as a whole, the assessed indicators meet the standards specified in the European guidelines

Hofvind S, Sakshaug S, Ursin G, Graff-Iversen S. Breast cancer incidence trends in Norway--explained by hormone therapy or mammographic screening? Int J Cancer 2012 Jun 15;130(12):2930-8.  DOI: 10.1002/ijc.26280 [doi]
In conclusion, the interpretation of breast cancer incidence trends in Norway from 1987 to 2009 is complicated because the NBCSP was introduced during a period with increasing HT use. Both factors likely contributed to the observed trends, and the role of each may vary across age groups

Javitt MC, Hendrick RE, Keen JD, Jorgensen KJ, Orton CG. Recent data show that mammographic screening of asymptomatic women is effective and essential. Medical Physics 2012 Jul;39(7):4047-50.
Raftery J, Chorozoglou M. Possible net harms of breast cancer screening: updated modelling of Forrest report. BMJ 2011 Dec 8;343.  DOI: 10.1136/bmj.d7627
Conclusions This analysis supports the claim that the introduction of breast cancer screening might have caused net harm for up to 10 years after the start of screening.

Seigneurin A, François O, Labarère J, udeville P, Monlong J, Colonna M. Overdiagnosis from non-progressive cancer detected by screening mammography: stochastic simulation study with calibration to population based registry data. BMJ 2011 Nov 23;343.  DOI: 10.1136/bmj.d7017
Conclusion Overdiagnosis from the detection of non-progressive disease by screening mammography was limited in 1991-2006 in Is+¿re. Because carcinoma in situ accounted for less than 15% of all incident breast cancer cases, its contribution to overdiagnosis was relatively limited and imprecise.

Sim MJH, Siva SP, Ramli IS, Fritschi L, Tresham J, Wylie EJ. Effect of false-positive screening mammograms on rescreening in Western Australia. Med J Aust 2012;196(11):693-5.
web desarrollada y mantenida por :